ACTIV-2: A Study for Outpatients with COVID-19
National Institute of Allergy and Infectious Diseases / “Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)”
GENDER: All
HEALTHY PARTICIPANTS: No
CONDITION: COVID-19
DEPARTMENT: Infectious Disease
Learn More About This Research Study
Please call Bob Bucklew or Brooke Willis at 216-844-4444 for more information or complete the online form below.
Purpose of the Study
The purpose of this study is to test several different medicines to see if they are safe and can help adults with COVID-19 get better. Researchers also want to know if the medicines can stop the disease from getting worse so that people don’t have to go to the hospital. Participants in the study will be treated with either a study drug or a placebo and have 28 days of intensive follow-up after study drug administration followed by less frequent visits through 24 weeks. Study visits may be required after week 24 depending on the study drug.
Who Can Participate
The study is for adults 18 years and older who have tested positive for COVID-19 within the last 10 days and are at home with symptoms (fever, cough, trouble breathing or feeling “out of breath,” sore throat, body pain or muscle aches, tiredness, headache, chills, stuffy or runny nose, loss of taste or smell, nausea or throwing up, diarrhea).